Christina Marie Dieli-Conwright, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Resistance Training | 15 | 2021 | 164 | 8.160 |
Why?
|
Exercise | 30 | 2023 | 5611 | 3.050 |
Why?
|
Exercise Therapy | 11 | 2022 | 904 | 2.860 |
Why?
|
Breast Neoplasms | 30 | 2023 | 20774 | 2.720 |
Why?
|
Anthracyclines | 7 | 2022 | 288 | 2.310 |
Why?
|
Body Composition | 11 | 2023 | 2400 | 1.560 |
Why?
|
Postmenopause | 10 | 2022 | 2461 | 1.350 |
Why?
|
Sarcopenia | 3 | 2018 | 368 | 1.340 |
Why?
|
Physical Fitness | 9 | 2023 | 732 | 1.230 |
Why?
|
Androgen Antagonists | 4 | 2021 | 1350 | 1.070 |
Why?
|
Obesity | 16 | 2023 | 12705 | 0.960 |
Why?
|
Muscle, Skeletal | 10 | 2022 | 4933 | 0.920 |
Why?
|
Survivors | 6 | 2023 | 2286 | 0.900 |
Why?
|
Biliary Tract Neoplasms | 1 | 2023 | 178 | 0.820 |
Why?
|
Oxygen Consumption | 3 | 2020 | 1869 | 0.760 |
Why?
|
Nuclear Receptor Coactivator 1 | 2 | 2010 | 42 | 0.720 |
Why?
|
Nuclear Receptor Co-Repressor 2 | 2 | 2010 | 32 | 0.710 |
Why?
|
Estrogen Replacement Therapy | 3 | 2012 | 1202 | 0.690 |
Why?
|
Neoplasms | 9 | 2023 | 21596 | 0.660 |
Why?
|
Matrix Metalloproteinases | 1 | 2020 | 391 | 0.610 |
Why?
|
Electric Impedance | 3 | 2018 | 727 | 0.570 |
Why?
|
Pilot Projects | 9 | 2022 | 8297 | 0.560 |
Why?
|
Absorptiometry, Photon | 4 | 2018 | 1726 | 0.550 |
Why?
|
Overweight | 4 | 2023 | 2366 | 0.550 |
Why?
|
Cardiovascular Diseases | 5 | 2023 | 15108 | 0.540 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2023 | 987 | 0.530 |
Why?
|
Muscle Strength | 6 | 2021 | 586 | 0.530 |
Why?
|
Fasting | 1 | 2021 | 1589 | 0.520 |
Why?
|
Mitochondrial Proteins | 1 | 2021 | 995 | 0.510 |
Why?
|
Motor Activity | 5 | 2014 | 2714 | 0.510 |
Why?
|
Central Nervous System Neoplasms | 1 | 2023 | 895 | 0.500 |
Why?
|
Hormone Replacement Therapy | 2 | 2011 | 744 | 0.500 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1340 | 0.490 |
Why?
|
Subcutaneous Fat | 1 | 2017 | 391 | 0.480 |
Why?
|
Myostatin | 2 | 2012 | 124 | 0.470 |
Why?
|
Recreation | 1 | 2013 | 115 | 0.440 |
Why?
|
Prostatic Neoplasms | 4 | 2021 | 11039 | 0.430 |
Why?
|
Dietary Proteins | 1 | 2017 | 963 | 0.410 |
Why?
|
Health Status Disparities | 1 | 2023 | 1794 | 0.400 |
Why?
|
Quality of Life | 10 | 2022 | 12730 | 0.400 |
Why?
|
Humans | 68 | 2023 | 742088 | 0.390 |
Why?
|
Female | 47 | 2023 | 379592 | 0.380 |
Why?
|
Insulin Resistance | 2 | 2022 | 3861 | 0.380 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2019 | 1509 | 0.370 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 11472 | 0.350 |
Why?
|
Endometrial Neoplasms | 2 | 2023 | 1351 | 0.350 |
Why?
|
Estrogens | 3 | 2012 | 1562 | 0.340 |
Why?
|
Middle Aged | 30 | 2022 | 213127 | 0.330 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2009 | 129 | 0.330 |
Why?
|
Muscle Cells | 1 | 2009 | 196 | 0.320 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2016 | 2014 | 0.310 |
Why?
|
RNA, Messenger | 6 | 2016 | 13029 | 0.310 |
Why?
|
Neoadjuvant Therapy | 3 | 2017 | 2721 | 0.290 |
Why?
|
Endothelium, Vascular | 1 | 2019 | 4455 | 0.290 |
Why?
|
Physical Exertion | 1 | 2009 | 695 | 0.280 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13655 | 0.270 |
Why?
|
Monitoring, Physiologic | 2 | 2014 | 1737 | 0.270 |
Why?
|
Gene Expression | 4 | 2016 | 7790 | 0.260 |
Why?
|
Fatigue | 4 | 2022 | 1526 | 0.260 |
Why?
|
Receptors, Estrogen | 2 | 2010 | 2186 | 0.250 |
Why?
|
Neoplasm Staging | 6 | 2019 | 11001 | 0.240 |
Why?
|
Adult | 25 | 2022 | 213712 | 0.240 |
Why?
|
Muscle Proteins | 1 | 2009 | 1159 | 0.230 |
Why?
|
Medical Oncology | 4 | 2023 | 2235 | 0.230 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2021 | 9185 | 0.230 |
Why?
|
California | 3 | 2017 | 1400 | 0.220 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 6754 | 0.210 |
Why?
|
Triglycerides | 2 | 2022 | 2450 | 0.200 |
Why?
|
Exercise Test | 1 | 2009 | 2075 | 0.200 |
Why?
|
Estradiol | 1 | 2009 | 2021 | 0.200 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 9941 | 0.200 |
Why?
|
Carcinoembryonic Antigen | 1 | 2022 | 347 | 0.190 |
Why?
|
Hematologic Neoplasms | 2 | 2023 | 1820 | 0.190 |
Why?
|
Matrix Metalloproteinase 10 | 1 | 2020 | 6 | 0.190 |
Why?
|
Energy Metabolism | 4 | 2023 | 2896 | 0.190 |
Why?
|
Blood Pressure | 1 | 2016 | 8541 | 0.180 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1515 | 0.180 |
Why?
|
Follistatin | 2 | 2012 | 141 | 0.180 |
Why?
|
Tissue Inhibitor of Metalloproteinase-2 | 1 | 2020 | 68 | 0.180 |
Why?
|
Anthropometry | 3 | 2010 | 1350 | 0.180 |
Why?
|
Ki-67 Antigen | 1 | 2022 | 644 | 0.180 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2020 | 58 | 0.180 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2020 | 141 | 0.180 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2020 | 149 | 0.180 |
Why?
|
Inflammation | 2 | 2017 | 10578 | 0.180 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 379 | 0.170 |
Why?
|
Abdominal Fat | 1 | 2020 | 223 | 0.160 |
Why?
|
Treatment Outcome | 8 | 2020 | 62966 | 0.160 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2020 | 472 | 0.150 |
Why?
|
Daunorubicin | 1 | 2017 | 149 | 0.150 |
Why?
|
Aged | 17 | 2023 | 162944 | 0.150 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2020 | 436 | 0.150 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2020 | 638 | 0.140 |
Why?
|
Risk Factors | 6 | 2022 | 72145 | 0.140 |
Why?
|
Male | 18 | 2023 | 349538 | 0.140 |
Why?
|
Eating | 1 | 2023 | 1535 | 0.140 |
Why?
|
Biopsy | 3 | 2017 | 6756 | 0.130 |
Why?
|
Women's Health | 2 | 2022 | 2034 | 0.130 |
Why?
|
Muscle Fatigue | 1 | 2015 | 82 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2022 | 12344 | 0.120 |
Why?
|
Regional Blood Flow | 1 | 2018 | 1525 | 0.120 |
Why?
|
Body Mass Index | 3 | 2023 | 12695 | 0.120 |
Why?
|
Gene Expression Regulation | 2 | 2009 | 12071 | 0.120 |
Why?
|
Quadriceps Muscle | 1 | 2015 | 144 | 0.120 |
Why?
|
Calorimetry, Indirect | 1 | 2014 | 183 | 0.120 |
Why?
|
Cholesterol | 1 | 2022 | 2895 | 0.120 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 1835 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 4751 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1215 | 0.110 |
Why?
|
Androgens | 1 | 2021 | 1271 | 0.110 |
Why?
|
Faculty | 2 | 2013 | 383 | 0.110 |
Why?
|
Shoulder Joint | 1 | 2019 | 693 | 0.110 |
Why?
|
Range of Motion, Articular | 1 | 2019 | 1577 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2020 | 5062 | 0.110 |
Why?
|
Prostate-Specific Antigen | 1 | 2022 | 2458 | 0.110 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 4414 | 0.110 |
Why?
|
Follistatin-Related Proteins | 1 | 2012 | 48 | 0.110 |
Why?
|
Waist Circumference | 1 | 2016 | 917 | 0.100 |
Why?
|
Premenopause | 1 | 2016 | 1033 | 0.100 |
Why?
|
Mastectomy | 1 | 2020 | 1789 | 0.100 |
Why?
|
Home Care Services | 1 | 2018 | 602 | 0.100 |
Why?
|
Adiponectin | 1 | 2017 | 1099 | 0.100 |
Why?
|
Activin Receptors, Type II | 1 | 2012 | 127 | 0.100 |
Why?
|
Diet | 4 | 2023 | 7923 | 0.100 |
Why?
|
Protein Isoforms | 1 | 2016 | 1727 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 3471 | 0.100 |
Why?
|
Athletic Performance | 1 | 2011 | 95 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2450 | 0.090 |
Why?
|
Glucose | 1 | 2022 | 4391 | 0.090 |
Why?
|
Actigraphy | 1 | 2014 | 488 | 0.090 |
Why?
|
Activities of Daily Living | 1 | 2019 | 2414 | 0.090 |
Why?
|
Young Adult | 7 | 2023 | 56350 | 0.090 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2009 | 79 | 0.090 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 1813 | 0.090 |
Why?
|
Progestins | 1 | 2011 | 303 | 0.080 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2021 | 2407 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 2956 | 0.080 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2009 | 424 | 0.080 |
Why?
|
Sleep | 2 | 2021 | 4604 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2017 | 3199 | 0.080 |
Why?
|
Progesterone | 1 | 2012 | 773 | 0.080 |
Why?
|
Blood Chemical Analysis | 1 | 2009 | 440 | 0.070 |
Why?
|
Creatine Kinase | 1 | 2009 | 694 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8621 | 0.070 |
Why?
|
Physical Endurance | 1 | 2009 | 370 | 0.070 |
Why?
|
Medication Adherence | 1 | 2018 | 2055 | 0.070 |
Why?
|
Human Growth Hormone | 1 | 2011 | 683 | 0.070 |
Why?
|
Child | 7 | 2023 | 77478 | 0.070 |
Why?
|
DNA, Complementary | 1 | 2009 | 2049 | 0.070 |
Why?
|
Bone Density | 1 | 2018 | 3469 | 0.070 |
Why?
|
Tumor Microenvironment | 1 | 2017 | 3564 | 0.070 |
Why?
|
Menopause | 1 | 2013 | 1621 | 0.060 |
Why?
|
Lipids | 1 | 2016 | 3302 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2012 | 1675 | 0.060 |
Why?
|
Dietary Supplements | 1 | 2017 | 3294 | 0.060 |
Why?
|
Tamoxifen | 1 | 2009 | 980 | 0.060 |
Why?
|
C-Reactive Protein | 1 | 2016 | 3766 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7901 | 0.060 |
Why?
|
Adolescent | 8 | 2023 | 85649 | 0.060 |
Why?
|
Transcriptional Activation | 1 | 2010 | 1782 | 0.060 |
Why?
|
Cognition | 1 | 2021 | 6722 | 0.060 |
Why?
|
Macrophages | 1 | 2017 | 5655 | 0.050 |
Why?
|
Research Design | 1 | 2018 | 5979 | 0.050 |
Why?
|
Administrative Personnel | 1 | 2023 | 187 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 24913 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8328 | 0.050 |
Why?
|
Breast | 1 | 2011 | 1958 | 0.050 |
Why?
|
Blood Glucose | 1 | 2016 | 6249 | 0.050 |
Why?
|
Disease Progression | 1 | 2017 | 13256 | 0.050 |
Why?
|
Adipose Tissue | 2 | 2010 | 3278 | 0.050 |
Why?
|
Testosterone | 1 | 2011 | 2401 | 0.050 |
Why?
|
Technology | 1 | 2023 | 303 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6171 | 0.050 |
Why?
|
Geriatric Assessment | 2 | 2022 | 1369 | 0.050 |
Why?
|
Diet, Fat-Restricted | 1 | 2022 | 317 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2236 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15194 | 0.040 |
Why?
|
RNA | 1 | 2009 | 2747 | 0.040 |
Why?
|
Doxorubicin | 2 | 2017 | 2215 | 0.040 |
Why?
|
20-Hydroxysteroid Dehydrogenases | 1 | 2017 | 6 | 0.040 |
Why?
|
Hydroxysteroid Dehydrogenases | 1 | 2017 | 29 | 0.040 |
Why?
|
Aldehyde Reductase | 1 | 2017 | 66 | 0.040 |
Why?
|
Arteries | 1 | 2022 | 1118 | 0.040 |
Why?
|
Chemokine CCL3 | 1 | 2017 | 83 | 0.040 |
Why?
|
Chemokine CCL11 | 1 | 2017 | 129 | 0.040 |
Why?
|
Trail Making Test | 1 | 2017 | 57 | 0.040 |
Why?
|
Alcohol Oxidoreductases | 1 | 2017 | 170 | 0.040 |
Why?
|
Proteins | 1 | 2012 | 6096 | 0.040 |
Why?
|
United States | 2 | 2022 | 69693 | 0.040 |
Why?
|
Vegetables | 1 | 2022 | 1179 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 974 | 0.030 |
Why?
|
Smoking | 1 | 2013 | 8969 | 0.030 |
Why?
|
Ergometry | 1 | 2015 | 17 | 0.030 |
Why?
|
Prognosis | 1 | 2016 | 29010 | 0.030 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2017 | 297 | 0.030 |
Why?
|
Energy Intake | 1 | 2023 | 2147 | 0.030 |
Why?
|
Isometric Contraction | 1 | 2015 | 147 | 0.030 |
Why?
|
Fractals | 1 | 2015 | 123 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39004 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2017 | 579 | 0.030 |
Why?
|
Cytokines | 1 | 2009 | 7317 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 617 | 0.030 |
Why?
|
Aging | 1 | 2013 | 8626 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2017 | 651 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2011 | 21719 | 0.030 |
Why?
|
Self Report | 2 | 2017 | 3548 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2023 | 3038 | 0.030 |
Why?
|
Lymphocytes | 1 | 2020 | 2614 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1525 | 0.030 |
Why?
|
Caregivers | 1 | 2023 | 2074 | 0.020 |
Why?
|
Adipocytes | 1 | 2017 | 1182 | 0.020 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 2304 | 0.020 |
Why?
|
Menarche | 1 | 2013 | 513 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2010 | 6365 | 0.020 |
Why?
|
Electromyography | 1 | 2015 | 1391 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3210 | 0.020 |
Why?
|
Electric Stimulation | 1 | 2015 | 1770 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2020 | 5975 | 0.020 |
Why?
|
Child Development | 1 | 2021 | 2222 | 0.020 |
Why?
|
Leisure Activities | 1 | 2010 | 311 | 0.020 |
Why?
|
Animals | 2 | 2022 | 168561 | 0.020 |
Why?
|
Plethysmography | 1 | 2008 | 180 | 0.020 |
Why?
|
Thinness | 1 | 2011 | 479 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2015 | 1538 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9410 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5948 | 0.020 |
Why?
|
Pregnancy | 2 | 2021 | 29087 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2019 | 3215 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3070 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2017 | 6974 | 0.010 |
Why?
|
Age Factors | 2 | 2013 | 18355 | 0.010 |
Why?
|
Prospective Studies | 2 | 2021 | 53187 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5163 | 0.010 |
Why?
|
Reference Values | 1 | 2010 | 4982 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2010 | 19862 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16665 | 0.010 |
Why?
|
Health Surveys | 1 | 2010 | 4030 | 0.010 |
Why?
|
Aged, 80 and over | 3 | 2010 | 57683 | 0.010 |
Why?
|
Equipment Design | 1 | 2008 | 3582 | 0.010 |
Why?
|
Heart Rate | 1 | 2010 | 4091 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12017 | 0.010 |
Why?
|
Depression | 1 | 2017 | 7733 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15244 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2010 | 7770 | 0.010 |
Why?
|
Software | 1 | 2010 | 4434 | 0.010 |
Why?
|
Mice | 1 | 2022 | 81045 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15056 | 0.010 |
Why?
|
Sex Factors | 1 | 2008 | 10392 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14720 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 40450 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13853 | 0.010 |
Why?
|